Literature DB >> 11410329

Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases.

C Sotiriou1, M Lacroix, L Lespagnard, D Larsimont, M Paesmans, J J Body.   

Abstract

Breast cancers frequently metastasize to bone where they often cause extensive tumor-induced osteoclast-mediated osteolysis. Interleukin-6 (IL-6) and IL-11 are two cytokines exhibiting osteolytic properties through their potent stimulation of osteoclast formation. We investigated the expression of IL-6 and IL-11 in 99 invasive primary breast tumors by immunohistochemistry and in situ hybridization, respectively. We examined their potential as predictive factors for further development of bone metastases. 52/90 (57%) of tumor samples showed IL-6 cytoplasmic immunostaining. There was no significant association between IL-6 status and any of the classical prognostic factors. 15/89 (17%) of the tumor samples expressed IL-11 mRNA. A positive IL-11 mRNA status was associated with a low tumor grade (P=0.05). Tumors expressing IL-11 mRNA had a statistically significant (P=0.002) higher rate of bone metastases occurrence (12/15, 80%) than IL-11 negative tumors (27/74, 37%). Such association was not found for IL-6. Our findings demonstrate for the first time IL-11 gene expression in some primary invasive breast tumors and suggest the potential of this cytokine as possible biological predictive factor for the development of bone metastases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11410329     DOI: 10.1016/s0304-3835(01)00524-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  23 in total

1.  Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway.

Authors:  Yibin Kang; Wei He; Shaun Tulley; Gaorav P Gupta; Inna Serganova; Chang-Rung Chen; Katia Manova-Todorova; Ronald Blasberg; William L Gerald; Joan Massagué
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

2.  Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer.

Authors:  Yuzo Furuya; Remon Nishio; Akira Junicho; Osamu Nagakawa; Hideki Fuse
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

3.  Potential prognostic biomarkers for bone metastasis from hepatocellular carcinoma.

Authors:  Zuo-Lin Xiang; Zhao-Chong Zeng; Zhao-You Tang; Jia Fan; Jian He; Hai-Ying Zeng; Xiao-Dong Zhu
Journal:  Oncologist       Date:  2011-06-10

Review 4.  Bisphosphonates in the treatment of metastatic breast cancer.

Authors:  J J Body
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

5.  Interleukin 11 inhibits human trophoblast invasion indicating a likely role in the decidual restraint of trophoblast invasion during placentation.

Authors:  Premila Paiva; Lois A Salamonsen; Ursula Manuelpillai; Evdokia Dimitriadis
Journal:  Biol Reprod       Date:  2008-11-05       Impact factor: 4.285

6.  Expression of interleukin-11 and interleukin-11 receptor alpha in human colorectal adenocarcinoma; immunohistochemical analyses and correlation with clinicopathological factors.

Authors:  Kazuyuki Yamazumi; Toshiyuki Nakayama; Takafumi Kusaba; Chun Yang Wen; Ayumi Yoshizaki; Yuichi Yakata; Takeshi Nagayasu; Ichiro Sekine
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

7.  Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer.

Authors:  Abigail E Witt; Lisa M Hines; Nicole L Collins; Yanhui Hu; Ruwanthi N Gunawardane; Donna Moreira; Jacob Raphael; Daniel Jepson; Malvika Koundinya; Andreas Rolfs; Barbara Taron; Steven J Isakoff; Joan S Brugge; Joshua LaBaer
Journal:  J Proteome Res       Date:  2006-03       Impact factor: 4.466

8.  Cryoablation and Meriva have strong therapeutic effect on triple-negative breast cancer.

Authors:  Dinesh Chandra; Arthee Jahangir; Francois Cornelis; Klara Rombauts; Lydie Meheus; Cheryl L Jorcyk; Claudia Gravekamp
Journal:  Oncoimmunology       Date:  2015-05-29       Impact factor: 8.110

9.  Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130/STAT3 pathway.

Authors:  Li Ren; Xia Wang; Zuoliang Dong; Jun Liu; Shiwu Zhang
Journal:  Med Oncol       Date:  2013-06-28       Impact factor: 3.064

10.  The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling.

Authors:  Eui Jung Moon; Stephano S Mello; Caiyun G Li; Jen-Tsan Chi; Kaushik Thakkar; Jacob G Kirkland; Edward L Lagory; Ik Jae Lee; Anh N Diep; Yu Miao; Marjan Rafat; Marta Vilalta; Laura Castellini; Adam J Krieg; Edward E Graves; Laura D Attardi; Amato J Giaccia
Journal:  Nat Commun       Date:  2021-07-14       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.